Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study.

Stocchi F, Rascol O, Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow CW.

Ann Neurol. 2010 Jul;68(1):18-27. doi: 10.1002/ana.22060. Erratum in: Ann Neurol. 2010 Sep;68(3):412-3.

PMID:
20582993
3.

The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.

Stocchi F.

Expert Opin Pharmacother. 2006 Jul;7(10):1399-407. Review.

PMID:
16805724
4.

[Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination].

Castro A, Valldeoriola F, Linazasoro G, Rodriguez-Oroz MC, Stochi F, Marin C, Rodriguez M, Vaamonde J, Jenner P, Alvarez L, Pavon N, Macias R, Luquin MR, Hernandez B, Grandas F, Gimenez-Roldan S, Tolosa E, Obeso JA.

Neurologia. 2005 May;20(4):180-8. Review. Spanish.

PMID:
15891947
5.

Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.

Reichmann H, Emre M.

Expert Rev Neurother. 2012 Feb;12(2):119-31. doi: 10.1586/ern.11.203. Review. Erratum in: Expert Rev Neurother. 2012 May;12(5):628.

PMID:
22288667
6.
7.

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

Najib J.

Clin Ther. 2001 Jun;23(6):802-32; discussion 771. Review.

PMID:
11440283
8.

Factors associated with motor fluctuations and dyskinesia in Parkinson Disease: potential role of a new melevodopa plus carbidopa formulation (Sirio).

Stocchi F, Marconi S.

Clin Neuropharmacol. 2010 Jul;33(4):198-203. doi: 10.1097/WNF.0b013e3181de8924. Review.

PMID:
20414107
9.

[Inhibition of the COMPT with entacapone in the treatment of motor fluctuations in Parkinson disease].

Kulisevsky J.

Neurologia. 1999 Aug-Sep;14(7):349-58. Review. Spanish.

PMID:
10570622
10.

Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.

Pahwa R.

J Am Med Dir Assoc. 2006 Sep;7(7 Suppl 2):4-10. Review.

PMID:
17948613
11.

Entacapone.

Müller T.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):983-93. doi: 10.1517/17425255.2010.502167. Review.

PMID:
20572781
12.

Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.

Rascol O.

Eur J Neurol. 2011 Mar;18 Suppl 1:3-10. doi: 10.1111/j.1468-1331.2010.03326.x. Review.

PMID:
21255197
13.

Extending levodopa action: COMT inhibition.

Martínez-Martín P, O'Brien CF.

Neurology. 1998 Jun;50(6 Suppl 6):S27-32; discussion S44-8. Review.

PMID:
9633684
14.
15.

Clinical advantages of COMT inhibition with entacapone - a review.

Gordin A, Kaakkola S, Teräväinen H.

J Neural Transm (Vienna). 2004 Oct;111(10-11):1343-63. Review.

PMID:
15340869
16.

Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation.

Jenner P.

Neurology. 2004 Jan 13;62(1 Suppl 1):S47-55. Review.

PMID:
14718680
17.

Entacapone in the management of Parkinson's disease.

Henchcliffe C, Waters C.

Expert Opin Pharmacother. 2002 Jul;3(7):957-63. Review.

PMID:
12083995
18.
19.

Entacapone/levodopa/carbidopa combination tablet: Stalevo.

[No authors listed]

Drugs R D. 2003;4(5):310-1. Review.

PMID:
12952501
20.

Entacapone in the treatment of Parkinson's disease.

Schrag A.

Lancet Neurol. 2005 Jun;4(6):366-70. Review.

PMID:
15907741
Items per page

Supplemental Content

Support Center